Esperion Therapeutics completed the acquisition of Corstasis Therapeutics for $75 million in upfront cash. The deal includes potential milestone payments of up to $180 million based on regulatory and commercial achievements. Esperion secured $25 million in additional term loans and raised $50 million through a royalty purchase agreement with Athyrium Opportunities IV Acquisition LP to fund the acquisition. The royalty agreement covers a portion of royalties and milestones from the Otsuka Pharmaceutical License and Collaboration Agreement until the purchaser receives $100 million. The acquisition adds Enbumyst (bumetanide nasal spray), an FDA-approved treatment for edema associated with congestive heart failure, hepatic, and renal disease, to Esperion's commercial portfolio.